ImmunityBio
IBRX
IBRX
146 hedge funds and large institutions have $292M invested in ImmunityBio in 2023 Q4 according to their latest regulatory filings, with 30 funds opening new positions, 57 increasing their positions, 28 reducing their positions, and 13 closing their positions.
New
Increased
Maintained
Reduced
Closed
more capital invested
Capital invested by funds: $ → $
more call options, than puts
Call options by funds: $ | Put options by funds: $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
12% more funds holding
Funds holding: 130 → 146 (+16)
1.24% more ownership
Funds ownership: 7.47% → 8.71% (+1.2%)
Holders
146
Holding in Top 10
1
Calls
$14.5M
Puts
$5.13M
Top Buyers
| 1 | +$33.9M | |
| 2 | +$4.27M | |
| 3 | +$4.12M | |
| 4 |
Morgan Stanley
New York
|
+$4.02M |
| 5 |
Rafferty Asset Management
New York
|
+$3.71M |
Top Sellers
| 1 | -$6.76M | |
| 2 | -$5.87M | |
| 3 | -$1.36M | |
| 4 |
National Bank of Canada
Montreal,
Quebec, Canada
|
-$1.07M |
| 5 |
Group One Trading
Chicago,
Illinois
|
-$755K |